Christopher Salerno
Overview
Explore the profile of Christopher Salerno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pagani F, Cowger J, Jorde U, Salerno C, Naka Y, Bhat G, et al.
J Heart Lung Transplant
. 2025 Mar;
PMID: 40064407
Background: Contemporary durable left ventricular assist devices (LVAD) have established current benchmarks for patient outcomes, but introduction of more novel technology is lacking. The BrioVAD System (BrioHealth Solutions, Burlington, MA)...
2.
Kanelidis A, Gozdecki L, Belkin M, Kalantari S, Nguyen A, Chung B, et al.
J Card Fail
. 2025 Feb;
PMID: 39954845
Background: Despite improvements in hemocompatibility-related adverse events (HRAEs) with the HeartMate 3 left ventricular assist device (LVAD), hemodynamic-related events (HDREs), such as right ventricular failure (RVF) and aortic insufficiency, still...
3.
Alam A, Lee C, Kanwar M, Moayedi Y, Bernhardt A, Takeda K, et al.
J Heart Lung Transplant
. 2024 Dec;
PMID: 39730081
Heart transplantation remains a critical therapy for patients with end-stage heart failure, offering incremental survival and improved quality of life. One of the key components behind the success of heart...
4.
Kanelidis A, Randazzo M, Kalantari S, Smith B, Nguyen A, Chung B, et al.
Eur Heart J Open
. 2024 Sep;
4(5):oeae072.
PMID: 39328214
Aims: Pulmonary artery catheter haemodynamics are associated with improved survival in cardiogenic shock (CS). We investigated the utility of aortic pulsatility index (API) and cardiac power output (CPO) as surrogates...
5.
Goldstein D, Kanwar M, Cowger J, Patel S, Meyer D, Molina E, et al.
J Heart Lung Transplant
. 2024 Jul;
43(11):1873-1880.
PMID: 39019352
While notable improvements in survival, the incidence of hemocompatibility-related adverse events, hospitalizations, and cost have been demonstrated with the only commercially available durable left ventricular assist device, a category of...
6.
Kent J, Nordgren R, Ahn D, Lysandrou M, Diaz A, Fenton D, et al.
Artif Organs
. 2024 Jun;
48(11):1288-1296.
PMID: 38924545
Background: Portable ex vivo lung perfusion during lung transplantation is a resource-intensive technology. In light of its increasing use, we evaluated the cost-effectiveness of ex vivo lung perfusion at a...
7.
Jawaid O, Salerno C, Ravichandran A
Heart Fail Clin
. 2023 Nov;
20(1):83-89.
PMID: 37953024
Left ventricular assist devices (LVADs) or cardiac transplantation are the two prevailing methods of treating patients with end-stage heart failure. The availability of donor hearts is insufficient to meet the...
8.
Impact of prophylactic donor heart tricuspid valve annuloplasty on outcomes in heart transplantation
Nishida H, Jeevanandam V, Salerno C, Nemoto A, Song T, Onsager D, et al.
J Cardiothorac Surg
. 2023 Oct;
18(1):288.
PMID: 37828522
Background: Tricuspid regurgitation(TR) following heart transplantation could adversely affect clinical outcomes. In an effort to reduce the incidence of TR, prophylactic donor heart tricuspid valve annuloplasty has been performed during...
9.
Nishida H, Jeevanandam V, Salerno C, Nemoto A, Song T, Onsager D, et al.
Interdiscip Cardiovasc Thorac Surg
. 2023 Jul;
36(7).
PMID: 37421402
Objectives: It remains unknown if the left atrial appendage closure (LAAC) at the time of left ventricular assist device (LVAD) surgery can reduce ischaemic cerebrovascular accidents. Methods: Consecutive 310 patients...
10.
Grinstein J, Belkin M, Kalantari S, Bourque K, Salerno C, Pinney S
J Am Coll Cardiol
. 2023 Jun;
82(1):70-81.
PMID: 37380306
Left ventricular assist devices (LVADs) provide lifesaving therapy for patients with advanced heart failure. The recognition of pump thrombosis, stroke, and nonsurgical bleeding as hemocompatibility-related adverse events (HRAEs) led to...